ECSP15023182A - Composiciones que comprenden vortioxetina y donepezilo - Google Patents

Composiciones que comprenden vortioxetina y donepezilo

Info

Publication number
ECSP15023182A
ECSP15023182A ECIEPI201523182A ECPI201523182A ECSP15023182A EC SP15023182 A ECSP15023182 A EC SP15023182A EC IEPI201523182 A ECIEPI201523182 A EC IEPI201523182A EC PI201523182 A ECPI201523182 A EC PI201523182A EC SP15023182 A ECSP15023182 A EC SP15023182A
Authority
EC
Ecuador
Prior art keywords
vortioxetine
donepezilo
compositions including
donepezil
treatment
Prior art date
Application number
ECIEPI201523182A
Other languages
English (en)
Inventor
Connie Morillo
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of ECSP15023182A publication Critical patent/ECSP15023182A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan composiciones farmacéuticas que comprenden vortioxetina y donepezilo y el uso de una composición de este tipo para el tratamiento de disfunciones cognitivas.
ECIEPI201523182A 2012-12-13 2015-06-09 Composiciones que comprenden vortioxetina y donepezilo ECSP15023182A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261736799P 2012-12-13 2012-12-13

Publications (1)

Publication Number Publication Date
ECSP15023182A true ECSP15023182A (es) 2015-12-31

Family

ID=49943326

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201523182A ECSP15023182A (es) 2012-12-13 2015-06-09 Composiciones que comprenden vortioxetina y donepezilo

Country Status (44)

Country Link
US (1) US9211288B2 (es)
EP (1) EP2931276B1 (es)
JP (1) JP6257641B2 (es)
KR (1) KR102171152B1 (es)
CN (1) CN104853755B (es)
AP (1) AP2015008498A0 (es)
AR (2) AR093939A1 (es)
AU (1) AU2013357308B2 (es)
BR (1) BR112015013675B1 (es)
CA (1) CA2893468C (es)
CL (1) CL2015001615A1 (es)
CR (1) CR20150303A (es)
CY (1) CY1120098T1 (es)
DK (1) DK2931276T3 (es)
DO (1) DOP2015000133A (es)
EA (1) EA028300B1 (es)
EC (1) ECSP15023182A (es)
ES (1) ES2663680T3 (es)
GE (1) GEP201706739B (es)
GT (1) GT201500143A (es)
HR (1) HRP20180333T1 (es)
HU (1) HUE036280T2 (es)
IL (1) IL239192B (es)
LT (1) LT2931276T (es)
MA (1) MA38253B1 (es)
ME (1) ME03029B (es)
MX (1) MX362886B (es)
MY (1) MY171802A (es)
NI (1) NI201500078A (es)
NO (1) NO2970700T3 (es)
NZ (1) NZ708595A (es)
PE (1) PE20151026A1 (es)
PH (1) PH12015501302A1 (es)
PL (1) PL2931276T3 (es)
PT (1) PT2931276T (es)
RS (1) RS56949B1 (es)
RU (1) RU2635528C2 (es)
SG (1) SG11201504483YA (es)
SI (1) SI2931276T1 (es)
SM (1) SMT201800135T1 (es)
TN (1) TN2015000235A1 (es)
UA (1) UA114016C2 (es)
WO (1) WO2014090929A1 (es)
ZA (1) ZA201504274B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN105315184B (zh) * 2015-06-26 2017-03-29 上海医药工业研究院 一种沃替西汀的制备方法及其中间体
EP3799873A1 (en) * 2015-07-17 2021-04-07 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
CN105534933A (zh) * 2016-01-19 2016-05-04 美吉斯制药（厦门）有限公司 一种沃替西汀口腔崩解片及其制备方法
MA45532A (fr) 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
ES2890326T3 (es) 2017-03-30 2022-01-18 Rundle Res Llc Inhibidores de vortioxetina y MAO para tratar la depresión
US20190216803A1 (en) 2017-03-30 2019-07-18 Rundle Research, LLC Methods of treating depression with vortioxetine
US10398691B2 (en) 2017-03-30 2019-09-03 Rundle Research, LLC Methods of treating depression
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK569087A (da) 1986-10-31 1988-05-01 Sumitomo Pharma Quinolin-derivater, deres fremstilling og anvendelse
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
DE3856594D1 (de) 1987-05-04 2008-11-27 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
EP0403713A1 (en) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Novel acetylcholinesterase inhibitors
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
TW200462B (es) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
WO1997038993A1 (en) 1996-04-12 1997-10-23 Hoechst Marion Roussel, Inc. Isatin derivatives as acetylcholinesterase inhibitors and analgesics
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
ES2297141T3 (es) 2002-03-29 2008-05-01 EISAI R&D MANAGEMENT CO., LTD. Derivados de (1-indanona)-(1,2,3,6-tetrahidropiridina).
EP1509232B1 (en) * 2002-05-31 2008-11-19 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
KR20050101537A (ko) * 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
CN101460156B (zh) * 2006-05-08 2011-06-08 帝国制药株式会社 抗痴呆药的经皮吸收制剂
WO2007146073A2 (en) * 2006-06-09 2007-12-21 Wyeth Method for enhancing cognitive function
MY150647A (en) 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
WO2009005519A1 (en) * 2007-06-29 2009-01-08 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Also Published As

Publication number Publication date
TN2015000235A1 (en) 2016-10-03
EP2931276B1 (en) 2018-02-21
RU2015122256A (ru) 2017-01-16
ES2663680T3 (es) 2018-04-16
WO2014090929A1 (en) 2014-06-19
AU2013357308B2 (en) 2017-08-31
CA2893468C (en) 2021-01-12
MX2015007269A (es) 2015-08-12
EA028300B1 (ru) 2017-10-31
BR112015013675A2 (pt) 2017-07-11
NI201500078A (es) 2016-02-15
PH12015501302B1 (en) 2016-02-01
AR093939A1 (es) 2015-07-01
HUE036280T2 (hu) 2018-06-28
ZA201504274B (en) 2016-11-30
DK2931276T3 (en) 2018-03-26
ME03029B (me) 2018-10-20
MY171802A (en) 2019-10-30
CN104853755A (zh) 2015-08-19
SI2931276T1 (en) 2018-05-31
US20150297585A1 (en) 2015-10-22
PL2931276T3 (pl) 2018-06-29
RS56949B1 (sr) 2018-05-31
NZ708595A (en) 2019-06-28
HK1212601A1 (en) 2016-06-17
PT2931276T (pt) 2018-03-19
BR112015013675B1 (pt) 2022-04-26
CR20150303A (es) 2016-07-07
IL239192B (en) 2019-03-31
AR125920A2 (es) 2023-08-23
GEP201706739B (en) 2017-09-25
AU2013357308A1 (en) 2015-06-18
RU2635528C2 (ru) 2017-11-13
JP2016502990A (ja) 2016-02-01
IL239192A0 (en) 2015-07-30
EP2931276A1 (en) 2015-10-21
KR20150095681A (ko) 2015-08-21
AP2015008498A0 (en) 2015-05-31
EA201590932A1 (ru) 2015-10-30
SMT201800135T1 (it) 2018-05-02
UA114016C2 (xx) 2017-04-10
NO2970700T3 (es) 2018-05-26
CL2015001615A1 (es) 2015-08-07
KR102171152B1 (ko) 2020-10-29
CY1120098T1 (el) 2018-12-12
DOP2015000133A (es) 2015-11-30
MX362886B (es) 2019-02-22
CN104853755B (zh) 2017-08-22
PH12015501302A1 (en) 2016-02-01
US9211288B2 (en) 2015-12-15
MA38253B1 (fr) 2017-10-31
SG11201504483YA (en) 2015-07-30
MA38253A1 (fr) 2017-02-28
LT2931276T (lt) 2018-04-10
CA2893468A1 (en) 2014-06-19
GT201500143A (es) 2016-01-22
JP6257641B2 (ja) 2018-01-10
PE20151026A1 (es) 2015-07-11
HRP20180333T1 (hr) 2018-04-06

Similar Documents

Publication Publication Date Title
NI201500078A (es) Composiciones que comprenden vortioxetina y donepezilo.
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX2015002409A (es) Métodos y composiciones para el tratamiento de una afección genética.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2015000942A1 (es) Compuestos de benceno sustituido.
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
SV2015005126A (es) Nuevos compuestos para el tratamiento del cáncer
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CL2013003625A1 (es) Compuestos derivados de tetrahidroquinolinas condensadas con un cicloalquilo; formulacion farmaceutica que los comprende; y uso como moduladores de receptores de crth2 en el tratamiento del asma, rinitis alergica o epoc.
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
BR112014026397A2 (pt) composição e uso de uma composição
UY34829A (es) Nueva dosificación y formulación
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.